ADVANCES IN OPIOID“NEWRESEARCH: FROM BENCH
TO THE BEDSIDE
”

INRC
2022

VALENCIA (SPAIN)
4 -8 July 2022 | Hotel Meliá Valenciathth

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

SCIENTIFIC COMMITTEE
Lucia Hipólito Cubedo (Spain)
Chair
José Morón-Concepción (USA)
Co-ChairReam Al-Hasani (USA)Alexis Bailey (UK)
Catherine Cahill (USA)Meritxell Canals (UK)
José de Andrés (Spain)
Rafael Maldonado (Spain)
Dominique Massote (France)
Nicolas Massaly (USA)Amynah Pradhan (USA)Maria Jose Sánchez-Catalán (Spain)
Tuan Trang (Canada)

2 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

INRC Acting President / Treasurer
Lee-Yuan Liu-Chen

Information Officer
Amynah Pradhan

EXECUTIVE COMMITTEEBrian Reed
Ream Al-Hasani
Emily Jutkiewicz
Andrea Bedini
Stefan Schulz
Eamonn Kelly
Jing-Gen Liu
Shogo Tokuyama
Minoru Narita

ADVANCES IN OPIOID“NEWRESEARCH: FROM BENCH
TO THE BEDSIDE
”

INRC
2022

| 3

4 |

TIME

21:30

20:30

20:00

19:30

19:00

18:30

18:00

17:30

17:00

16:30

16:00

15:30

15:00

14:30

14:00

13:30

13:00

12:30

12:00

11:30

11:00

10:30

10:00

09.30

09.00

08.30

WELCOME RECEPTION& OPENING CEREMONYREGISTRATION(DOCUMENT HAND-OUT)

MONDAY, JULY 4

POSTER SESSION 1

SYMPOSIUM 3

SYMPOSIUM 2

DATA BLITZ

HOT TOPICSSYMPOSIUM 1

SYMPOSIUM 4SYMPOSIUM 1
SYMPOSIUM 4

INRC BARPOSTER SESSION 2

SYMPOSIUM 5

FOUNDER’S LECTURELUNCHDATA BLITZ

HOT TOPICSYOUNG INVESTIGATORAWARDS
2020-2021-2022

THURSDAY, JULY 7

GET TOGETHERGUIDED VISIT TO CAC

MENTORING ACTIVITIESSYMPOSIUM 7

SYMPOSIUM 6

COFFEE BREAK

PLENARY LECTURE 2

WEDNESDAY, JULY 6

PLENARY LECTURE 1

TUESDAY, JULY 5GALA DINNER

CLOSING REMARKSAND FAREWELL

BUSINESS MEETING

COFFEE BREAKSYMPOSIUM 10

LUNCH

SYMPOSIUM 9SYMPOSIUM 8SYMPOSIUM 8

PLENARY LECTURE 3

FRIDAY JULY 8“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

SCHEDULE

Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

MONDAY 4TH JULY
From 06:00 pm

Registration at the Venue
07:00-08:30 pm

Welcome Reception and Opening Ceremony| 5

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

TUESDAY 5TH JULY
08:30-09:10 am
PLENARY LECTURE
Chair: Lucia Hipólito (University of Valencia)
n How did it come to be, and what is the trajectory?
Dr. Chris Evans (University of California Los Angeles)
09:10-09:20 am
Discussion
09:20-11:00 am
SYMPOSIUM 1
Development of KOR agonists as therapeutic agents
Chair: Lee-Yuan Liu-Chen (Temple University)n 09:20-09:40 am
KOR Agonists Reduce Neuroinflammation and Promote Remyelination in PreclinicalModels of Multiple Sclerosis
Thomas Prisinzano (University of Kentucky)n 09:40-10:00 am
Anti-Pruritic Effects of Kappa Opioid Receptor (KOR) Agonists: Evidence fromRodents to Humans
Saadet Inan (Temple University)
10:00 -10:20 am
COFFEE BREAK
n 10:20-10:40 am
A Newly Synthesized Kappa Opioid Receptor Agonist Ameliorates Acuteand Chronic Pain without Causing Sedation or Aversion in Mice
Hiroshi Nagase (University of Tsukuba)n 10:40-11:00 am
Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid
Receptor (KOR) in Male Mouse Brains: Lack of Connection with Conditioned
Place Aversion
Lee-Yuan Liu-Chen (Temple University)
11:00-11:10 am
Discussion

6 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia→ Tuesday 5th july

11:10-11:50 am
HOT TOPIC
Chemistry, structural biology and computational approaches to design new opioid
ligands
Chairs:Susruta Majumdar (UHSP/Washington University)
Nurulain Zaveri (Astraea Therapeutics)
n 11:10-11:20 am
Targeting the allosteric sodium binding pocket in mu opioid receptor
Susruta Majumdar (UHSP/Washington University)n 11:20-11:30 am
Structure-based discovery of novel chemotypes and functionalized ligands for
OUD targets
Vsevolod “Seva” Katritch (University of Southern California)
n 11:30-11:40 am
Taking two shots on goal with a single chemical entity- Using structure-based
design to tailor bifunctional opioid pharmacology of Nociception Opioid
Receptor (NOP) Ligands
Nurulain Zaveri (Astraea Therapeutics)
n 11:40-11:50 am
Structure, function and pharmacology of delta opioid receptor bitopic ligands
Tao Che (Washington University)
11:50 am-12:00 pm
Discussion
12:00-12:30 pm
DATA BLITZ
Chairs:Ream Al-Hasani (University of Health Sciences and Pharmacy/ Washington University)
Meritxell Canals (Nottingham University)
12:30-01:30 pm
LUNCH

| 7

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

→ Tuesday 5th july

01:30-02:50 pm
SYMPOSIUM 2
New tools for in-vivo studies of signaling and circuits
Chairs:Carrie Stine (University of Washington)
Patrick O’Neill (University of California Los Angeles)
n 01:30-01:50 pm
In vivo photopharmacology with caged opioid drugs and peptides
Matthew Banghart (University of California San Diego)
n 01:50-02:10 pm
Illuminating the dynamics of neuromodulators and their intracellular signals
Yao Chen (Washington University)n 02:10-02:30 pm
Next-gen opto-GPCRs: from cells to circuits
Patrick O’Neill (University of California Los Angeles)
n 02:30-02:50 pm
Genetically encoded opioid peptide sensors for detecting endogenous opioid release
Carrie Stine (University of Washington)
02:50-03:00 pm
Discussion
03:00-04:00 pm
SYMPOSIUM 3
The role of opioid receptors in headache disorders
Chair: Amynah Pradhan (Univeristy of Illinios Chicago)n 03:00-03:20 pm
Uncovering a neuroendocrine link to female-selective pain and migraineFrank Porreca (University of Arizona)n 03:20-03:40 pm
Differential role of mu and delta opioid receptors in migraine
Amynah Pradhan (University of Illinois Chicago)n 03:40-04:00 pm
Identification of NOP receptor agonists for the treatment of migraine
Katarzyna M. Targowska-Duda (Medical University of Lublin)
8 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia→ Tuesday 5th july

04:00-04:10 pm
Discussion
04:10-06:00 pm
POSTER SESSION (with coffee)| 9

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

WEDNESDAY 6TH JULY
08:30-9:10 am
PLENARY LECTURE
Chair: Amynah Pradhan (University of Illinois Chicago)n Opioid receptors: 30 years into brain function
Dr. Brigitte Kieffer (INSERM/University of Strasbourg France)
09:10-09:20 am
Discussion
09:20-11:00 am
SYMPOSIUM 4
Mechanisms of function of endogenous and exogenous opioids in pain, reward
and affective neural circuits
Chair: Grégory Scherrer (University of North Carolina at Chapel Hill)
n 09:20-09:40 am
Mu opioid receptor-mediated regulation of ventral pallidum mechanismsof addiction
Meaghan Creed (Washington University)n 09:40-10:00 am
Dynorphinergic control of amygdalo-striatal circuits for goal-directed action
Michael Bruchas (University of Washington)
10:00 -10:20 am
COFFEE BREAK
n 10:20-10:40 am
MOR-neurons in the dorsal raphe nucleus: role in reward and affective behaviors
Lola Welsch (University of Strasbourg/INSERM)
n 10:40-11:00 am
Regional and cell-type specific molecular architecture of the opioid system
in neural circuits
Grégory Scherrer (University of North Carolina at Chapel Hill)
11:00-11:10 am
Discussion

10 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia→ Wednesday 6th july

11:10-11:50 am
HOT TOPIC
Prefrontal cortical opioid systems: from synapses to affective-and pain-related
behavior
Chair: Hugo Tejeda (National Institute of Mental Health, National Institutes of Health)n 11:10-11:20 am
Genetic strategies targeting nociceptive and opioidergic cortical cell-types
Gregory Corder (University of Pennsylvania)
n 11:20-11:30 am
Enkephalin regulation of synaptic transmission in anterior cingulate cortex
Will Birdsong (University of Michigan)n 11:30-11:40 am
The role of the endogenous dynorphin / kappa-opioid receptor system in
regulating prefrontal cortical threat processing and circuit function
Huikun Wang (National Institute of Mental Health, National Institutes of Health)n 11:40-11:50 am
Mouse models of surgical and neuropathic pain produce distinct alterations to
the excitability of prodynorphin-expressing neurons in the prelimbic cortex
Patrick Sheets (Indiana University School of Medicine)
11:50 am-12:00 am
Discussion
12:00-12:30 pm
DATA BLITZ
Chairs:Ream Al-Hasani (University of Health Sciences and Pharmacy/ Washington University)
Meritxell Canals (Nottingham University)
12:30-01:30 pm
LUNCH

| 11

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

→ Wednesday 6th july

01:30-02:30 pm
FOUNDER’S LECTURE
n From CSF to reversal of opioid-induced damages to the brain
Fred Nyberg (Uppsala University)n Pain inhibition via peripheral opioid receptors
Christoph Stein (Charité Universitätsmedizin Berlin, Freie Universität Berlin)
02:30-03:50 pm
SYMPOSIUM 5
The gut-brain-axis: a key regulator of opioid pharmacology or just a gut feeling?
“The symposium is supported by the British Pharmacological Society”
Chairs:Anna Taylor (University of Alberta)
Alexis Bailey (St.George’s University of London)
n 02:30-02:50 pm
The Epithelium-Nociceptor Interaction in Opioid-Induced Dysbiosis
Hamid Akbarali (Virginia Commonwealth University)n 02:50-03:10 pm
Dose- and Sex-Dependent Bidirectional Relationships for Intravenous Fentanyl
Self-Administration and the Gut Microbiome
Michelle Ren (University of California Irvine)
n 03:10-03:30 pm
Gut-Brain Axis and Early Life Opioid Receptor Neurodevelopment: The Devil isin the Milk
Alexis Bailey (St.George’s University of London)n 03:30-03:50 pm
Daily Intermittent Fasting in Mice Enhances Opioid Pain Relief and Reduces
Side Effects
John Streicher (University of Arizona)
03:50-04:00 pm
Discussion

04:00-06:00 pm
POSTER SESSION (with coffee) Room Valentia A
12 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia→ Wednesday 6th july

08:15-09:30 pm
INRC BAR
Place: Àtic-Palau Alameda
Adress: Calle de Muñoz Seca,1 - 46010 Valencia.

| 13

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

THURSDAY 7TH JULY
08:30-10:10 am
YOUNG INVESTIGATOR AWARDS 2020,2021 AND 2022
Chair: Lee-Yuan and Liu-Chen (Temple University)
YIA 2020: Ream Al-Hasani (University of Health Sciences and Pharmacy/ Washington
University )YIA 2021: Richard M. Van Rijn (Purdue University)
YIA 2022: John Streicher (University of Arizona)n 08:30-09:20 am
YIA 2020: How the support of a scientific community advanced my research
Ream Al-Hasani (Washington University)n 09:20-10:10 am
YIA 2022: The Organization of Mu Opioid Receptor Signal Transduction Cascades
in the Spinal Cord by Heat Shock Protein 90
John Streicher (University of Arizona)
10:10-10:30 am
COFFEE BREAK
10:30-12:50 am
SYMPOSIUM 6
Sex specific opioid signaling: implications for pain management and abuse potential“MJ Kreek Memorial Symposium”
n 10:30-10:40 am
MJ Kreek Memorial
Brian Reed (Rockefeller University)
Chair: Anne Z. Murphy (Georgia State University)n 10:40-11:00 am
Impact of age and sex on mu opioid receptor signaling in the periaqueductal
gray of male and female rats
Anne Z. Murphy (Georgia State University)n 11:00-11:20 am
Time-dependent effects of oxycodone abstinence on thalamo-accumbens
synaptic plasticity and cue reinstatement
Yanaira Alonso-Carballo (University of Minnesota, Harvard University)
14 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia→ Thursday 7th july

n 11:20-11:40 am
Pain-associated fentanyl intake in males is driven by dynamic activity of ventral
tegmental area dopamine neurons
Jessica Higginbotham (Washington University)n 11:40-12:00 am
Probing PAG dopamine circuits in pain
Thomas L. Kash (University of North Carolina Chapel Hill)
12:50-01:00 pm
Discussion
12:30-01:30 pm
LUNCH
01:30-03:00 pm
SYMPOSIUM 7
Neonatal opioid exposure: immediate and long-term consequences
Chair: Julie A. Blendy (University of Pennsylvania)
n 01:30-01:50 pm
Neonatal Opioid Withdrawal Syndrome in mice impacts behavior and gene
expression
Shivon A. Robinson (University of Pennsylvania, Williams College)n 01:50-02:10 pm
Behavioral and brain transcriptomic adaptations in outbred CFW mice andinbred FVB substrain differences in a model for neonatal opioid withdrawal
syndrome
Camron D. Bryant (Boston University)n 02:10-02:30 pm
Perinatal oxycodone exposure affects developmental milestones and adultsensory and reward behavior in mice.
Marwa Mikati (Washington University)n 02:30-02:50 pm
The impact of prenatal methadone exposure on sensorimotor cortices
Brady Atwood (Indiana University)
02:50-03:00 pm
Discussion| 15

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

→ Thursday 7th july

04:00-05:30 pm
MENTORING ACTIVITIES
07:00 pm
VISIT TO CIUDAD DE LAS ARTES Y LAS CIENCIAS

Important: In case you are interested it is mandatory to notify your attendance
to inrc2022@viajeseci.es before 1st July.
n 06:50 pm
MEETING POINT AT:
Restaurante Contrapunto Les Arts
Av. del Profesor López Piñero, 1, 46013 Valencia)
n 07:00 pm
START OF THE VISIT(groups accompanied by guides)
08:00-09:30 am
GET TOGETHERn LOCATION
Restaurante Contrapunto Les Arts
Av. del Profesor López Piñero, 1, 46013 Valencia

Important: Please notify your attendance “by clicking” the activity assistanceat your web registration profile. Please notify before 1st July

16 |

Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

FRIDAY 8TH JULY
08:30-09:10 am
PLENARY LECTURE
Chair: José Morón-Concepción (Washington University)n Implantable wireless systems for the study and treatment of pain, substanceuse disorder, and overdose
Dr. Robert W. Gereau (Washington University)
09:10-09:20 am
Discussion
09:20-11:00 am
SYMPOSIUM 8
Dynorphin and KOR signaling controlling pain, cognition and stress responses
Chairs:Charles Chavkin (University of Washington)
Elyssa Margolis (University of California, San Francisco)n 09:20-09:40 amStress can reverse the sign of KOR signaling in midbrain dopamine neurons.
Elyssa Margolis (University of California San Francisco)n 09:40-10:00 am
Dissecting the accumbal dynorphinergic outputs underlying affective pain
Nicolas Massaly (Washington University)
10:00 -10:20 am
COFFEE BREAK
n 10:20-10:40 am
The role of the endogenous dynorphin / kappa-opioid receptor system in
regulating prefrontal cortical threat processing and circuit function
Hugo Tejeda (National Institute of Mental Health, National Institutes of Health)n 10:40-11:00 am
Stress potentiation of addiction risk: dynorphin-mediated cellular and circuitmechanisms
Charles Chavkin (University of Washington)
11:00-11:10 am
Discussion| 17

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

→ Friday 8th july

11:10 am-01:30 pm
SYMPOSIUM 9
Examination of pain and addiction: the hits, the misses, and the opportunities“The symposium is supported by the Instituteof NeuroImmune Pharmacology”
Chairs:Yolanda Campos-Jurado (Washington University)
Arbi Nazarian (Western University School of Medicine)
Sulie L. Chang (Institute of NeuroImmune Pharmacology/Seton Hall University)
Part I: Pain and opioid addiction
n 11:10-11: 30 am
Pain-induced impulsivity, the role of opioids, and where we go from here
Arbi Nazarian (Western University of Health Sciences)
n 11:30-11:50 am
Pain and opioid abuse: thinking outside the brain
S. Stevens Negus (Virginia Commonwealth University)n 11:50 am-12:10 pm
Opposing effects of striatal mu opioid receptor involvement in opioid mediatedanalgesia
Catherine Cahill (University of California Los Angeles)
12:10-12:20 pm
Discussion
Part II: Pain, alcohol addiction and opioid receptors
n 12:20-12:40 pm
Alcohol modulation of the pain system
Sulie L. Chang (Institute of NeuroImmune Pharmacology/Seton Hall University)n 12:40-01:00 pm
Which comes first, neuroimmunity or mu-opioid receptors? A pivotal
relationship to unravel inflammatory pain-induced alcohol use disorders
Javier Cuitavi (University of Valencia)

18 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia→ Friday 8th july

n 01:00-01:20 pm
Alcohol, sex and pain: a convoluted cocktail?
Yolanda Campos-Jurado (Washington University)
01:20-01:30 pm
Discussion
01:30-02:30 pm
LUNCH
02:30-03:50 pm
SYMPOSIUM 10
Opioids and cannabinoids for pain: translational research session
Chairs:
Kelly E. Dunn (Johns Hopkins University)
Lawrence Carey (University of Texas Health Science Center)
n 02:30-2:50 pm
Cannabinoid/opioid interactions in rhesus monkeys: effects of phytocannabinoidson opioid antinociception, withdrawal, and self-administration.
Lawrence Carey (University of Texas Health Science Center)
n 02:50-03:10 pm
Human Laboratory Examination of the Opioid-sparing Effects of Cannabinoids
Ziva D. Cooper (University of California Los Angeles)
n 03:10-3:30 pm
How Opioid Sensitivity May Play a Role in Cannabinoid Opioid-sparing Effects:
A Human Laboratory Examination
Kelly E. Dunn (Johns Hopkins University)n 03:30-03:50 pm
Examining the Association between Endocannabinoid System Gene Variants andthe Reinforcing and Analgesic Effects of Hydromorphone Measured in a Human
Laboratory Study
Cecilia L. Bergeria (Johns Hopkins University)
03:50-04:00 pm
Discussion| 19

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

→ Friday 8th july

04:00-04:20 pm
COFFEE BREAK
04:20-05:20 pm
BUSINESS MEETING
05:20 pm
CLOSING REMARKS AND FAREWELLn INRC Best Postern INRC/Brain Sciences PhD Award Ceremony
08:00 pm
GALA DINNER
n LOCATION
Hotel Balneario Las Arenas 5* GL
Eugenia Viñes, 22, 24, 46011 Valencia• Bus available. Route: from Hotel Melia to Hotel Las Arenas.
Ask Technical Secretariat for departure’s time
• All attendance should bring the dinner ticket with you.

Important: Please notify your attendance “by clicking” the activity assistanceat your web registration profile. Please notify before 1st July

20 |

Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

PLENARY SPEAKER

Brigitte Kieffer

Chris Evans

INSERM/Universityof Strasbourg France

UCLA, Departmentof Psychiatry

HOW DID IT COME TO BE, AND
WHAT IS THE TRAJECTORY?
Short biography
Dr. Chris Evans received his graduate
training in peptide chemistry at the UK
Medical Research Council ResearchInstitute in London. He then moved to
Stanford University for his postdoctoral
training with Dr. Jack Barchas where
his research focused on the myriad ofendogenous opioid peptides, confirming
their existence, understanding precursor
processing, and mapping the distribution of
opioid peptides throughout the mammalianbrain. In 1990, he moved to UCLA to begin
his independent career that centered oncontinued research of the opioid systembut focusing on the receptors. Currently,
he is the Hatos Professor and Director of
the Hatos Center for Neuropharmacology
at UCLA. He has published extensively inopioid neuropharmacology including theidentification of molecules constituting theendogenous opioid system. His interests
are in the evolution of the opioid system, inusing the conditional knockouts to identify
circuits involved in opioid functions andcreating effective drug outreach programs.

OPIOID RECEPTORS: 30 YEARS INTO
BRAIN FUNCTION
Short biography
Brigitte Kieffer is Research Director at
INSERM U1114/Dpt Psychiatry at the
University of Strasbourg, France and Adjunct
Professor in the Dpt Psychiatry at McGill
University, Montreal Canada. Dr. Kieffer
isolated the first gene encoding an opioid
receptor, opening an entire research field
towards understanding the molecular basisof opioid-controlled behaviors. Her genetic
dissection of the opioid system has brought
major advances in pain, addiction and mooddisorders research, as well as in the areaof molecular pharmacology and G protein
coupled receptor biology. She has received
numerous awards, including the Lounsbery(French and US Academies of Science) andthe Lamonica Award of Neurology (French
Academy of Science); in 2014 she received
the International L’OREAL-UNESCO Award
for Women in Science (European Laureate)
and was elected Member of the French
Academy of Sciences.

| 21

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

Robert W. Gereau

Washington University
School of Medicine

IMPLANTABLE WIRELESS SYSTEMSFOR THE STUDY AND TREATMENT
OF PAIN, SUBSTANCEDISORDER, AND OVERDOSE
Short biography
Dr. Robert Gereau is the Dr. Seymour
and Rose T. Brown Professor and Vice
Chair for Research in the Department ofAnesthesiology at Washington University

School of Medicine, where he also serves
as Director of the Washington University
Pain Center. His research program seeks tounderstand cellular and molecular changes
that underlie chronic pain conditions,and to develop new medications andtechnologies for the treatment of pain.
He was the recipient of the Frederick WL
Kerr Award for Basic Science Researchfrom the American Pain Society and theLandis Award for Outstanding Mentorshipfrom NINDS. Gereau serves on the Boardof Directors for the US Association for
the Study of Pain, as a member or chair ofseveral grant review panels, as Chair of theBoard of Scientific Counselors for NIDCR,
and as a member of advisory boards related
to strategic planning for pain research andthe NIH HEAL Initiative.

YOUNG INVESTIGATOR AWARD 2020

Ream Al-Hasani, PhD
HOW THE SUPPORT OF A SCIENTIFICCOMMUNITY ADVANCED MY
RESEARCH
Short biography
Ream Al-Hasani is an Assistant Professor in

the Center for Clinical Pharmacology at the
University of Health Sciences & Pharmacy
in St. Louis and Washington University
22 |in St. Louis. She earned her BS(Hons) in
Pharmacology from the University ofPortsmouth. Dr. Al-Hasani focused herinterests on addiction by pursuing a PhD
in Neuropharmacology at the Universityof Surrey with Ian Kitchen and Susanna
Hourani where she studied the involvementof adenosine A2 receptors in morphine andcocaine addiction. Dr. Al-Hasani completed
her post-doctoral training in the Departmentof Anesthesiology at Washington University
with Michael Bruchas where she used basic
research models to dissect the role of the
opioid circuitry in motivated behaviors. Dr. AlHasani identified two distinct subpopulationsof dynorphinergic neurons within the nucleus
accumbens that drive aversive and reward-

Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

related behaviors. She also uncovered anovel role for GABAergic projection neurons
from the ventral tegmental area to the ventral
nucleus accumbens in reward reinforcement.
This work was the basis for her Pathway
to Independence Award (K99/R00) fromthe National Institute on Drug Abuse. Dr.
Al-Hasani’s current research focuses on
better understanding opioid peptide releasedynamics and function in mouse models
of natural rewards and threats, during drug

withdrawal and following in utero exposure
to opioids. Dr. Al-Hasani has also discovered
a role for the kappa opioid system in cold
hypersensitivity. Dr. Al-Hasani received theCutting Edge Basic Research Award from the
National Institute on Drug Abuse, the Young
Investigator Award from the International
Narcotics Research Conference and the Brainand Behavior Foundation Young Investigator
Research Award.

YOUNG INVESTIGATOR AWARD 2021
Richard M. Van Rijn

Department of Medicinal
Chemistry
and Molecular Pharmacology, Purdue University
Septerna Inc,TOWARDS A TARGET CANDIDATEPROFILE FOR A G-PROTEIN-BIASEDDELTA OPIOID AGONIST FOR THE
TREATMENT OF ALCOHOL USE
DISORDER
Short biography
Richard van Rijn received a bachelor andmaster’s degree in Bio-pharmaceutical
Sciences from Leiden University, and a PhD
in molecular pharmacology of G-proteincoupled histamine receptors from VU university

Amsterdam. He expanded his GPCR skillset
via a postdoctoral position at the Ernest
Gallo Clinic and Research Center at UCSF,
studying behavioral pharmacology of opioid
receptors in relation to opioid and alcohol
use disorder. In 2013, he joined the faculty of
the Department of Medicinal Chemistry andMolecular Pharmacology at Purdue University.
His research program, supported by multiple
NIH grants, aimed to establish G-protein-biased
delta opioid agonism as potential treatment foralcohol use disorder, mood disorder and chronic
pain conditions. He obtained tenure in 2019,and performed a sabbatical in the researchgroup of Dr. Shoichet at UCSF to acquire skills
in large-scale docking of virtual drug libraries. In
2021, he was recruited by Septerna to aid their
GPCR-focused drug discovery programs.

| 23

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

INRC YOUNG INVESTIGATOR AWARD 2022
John M. Streicher

Department ofPharmacology, College ofMedicine,
University of Arizona,
Tucson AZ USA

THE ORGANIZATION OF MU OPIOID
RECEPTOR SIGNAL TRANSDUCTION
CASCADES IN THE SPINAL CORD BY
HEAT SHOCK PROTEIN 90
Short biography
John Streicher is an Associate Professor in
the Department of Pharmacology, Collegeof Medicine, at the University of Arizona.
His research program focuses mainly on themolecular mechanisms of signal transduction
by the opioid and cannabinoid receptors in
pain, while using these mechanisms to designnovel drug discovery strategies for analgesic
drugs with a better efficacy and side effectprofile than opioids. He earned his B.S. from
George Fox University in 1999, his M.S. from
Oregon Health and Science University in 2002,
and his Ph.D. from University of California –Los Angeles in 2009. His postdoctoral training
was with Laura Bohn at The Scripps ResearchInstitute from 2009 – 2012. His first faculty
position was at the University of New Englandin 2012, and he joined the University of
Arizona in his current position in 2015.

FOUNDER’S LECTURE

Fred Nyberg

Faculty of Pharmacy, Uppsala, University
P.O. Box 591, S-751 24
UPPSALA, Sweden

FROM CSF TO REVERSALOF OPIOID-INDUCED DAMAGESTO THE BRAIN
Short biography
Fred Nyberg is currently active as Senior
Professor at the Dept of Pharmaceutical
Biosciences at Uppsala University. He
received his PhD in 1981 on a thesis directed
to pituitary polypeptide hormones, andsubsequently performed postdoc studies on
24 |opioid peptides in relation to chronic pain andopioid addiction. In 1993 he was appointed as
Full Professor in Addiction Biology. Between
2002-2007 he served at the Swedish
Government as Head of Research Issues at the
National Drug Policy Coordinator and during
2008-2017 he was a member of the Advisory
Board on addictive drugs at the Social Ministry.
He was Chairman for his Department 19992006, and from 2006 to 2011 Dean at theFaculty of Pharmacy, Uppsala University. He
is an active member of INRC since 1982 andserved as president for the organization 20142018. Nyberg’s field of research includes
aspects on peptidergic mechanisms in chronic
pain and drug dependence but it also extends
to areas related to neuroendocrinology,
neurology and psychiatry. He has over 450
publications in internationally well-recognizedresearch journals.

Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

Christoph Stein

Charité Universitätsmedizin
Berlin, Germany
Freie Universität Berlin,
Germany

PAIN INHIBITION VIA PERIPHERALOPIOID RECEPTORS
Short biography
ChristophStein(orcid.org/00000001-5240-6836) studied Medicine at
Ludwig-Maximilians-University(LMU)
München, Germany, and received training
in Anesthesiology (Klaus Peter, James
Cottrell), Pain Medicine (Wilbert Fordyce,
John Liebeskind) and Neuropharmacology(Albert Herz) at State University of
New York, University of California Los
Angeles, LMU and Max-Planck Institutefor Psychiatry (München, Germany). He
then accepted a faculty position at Johns
Hopkins University and established aresearch group at the National Institute on
Drug Abuse (Baltimore, USA). In 1997 heassumed the Chair of Anaesthesiology andIntensive Care Medicine at Freie Universität
Berlin, Germany (since 2003: CharitéCampus Benjamin Franklin) and built
an interdisciplinary research laboratory
including neuroscientists, pharmacologists
and clinicians. His work has focused onmechanisms underlying opioid analgesic
effects outside the central nervous systemwith the aim to avoid adverse side effects.

| 25

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

POSTERSSESSION POSTER 1
14.

FUNCTIONAL SELECTIVITY OF KAPPA OPIOID RECEPTOR: FOCUS ON ENDOGENOUS
AGONISTS
Luca, Zangrandi, Charitém Austria

54.

DELTA OPIOID RECEPTORS IN CANNABIDIOL ANTIALLODYNIC, ANXIOLYTIC AND
ANTIDEPRESSANT EFFECTS
Gaborit, Marion, INCI-CNRS, France

72.

EVALUATION OF SYNERGISTIC EFFECTS BETWEEN THC AND MORPHINE AND
THE POSSIBLE MOR-CB1 HETEROMERIZATION IN HUMAN CELL MODELS COEXPRESSING MOR AND CB1
Elisabetta, Cuna, Dept. Pharmacy and Biotechnology - University of Bologna, Italy

83.

EXPLORING THE SIGNALLING BIAS AND EFFICACY OF CARFENTANIL
Nokomis Ramos-Gonzalez, Nokomis, University of Bristol, United Kingdom

91.

AN ELECTROCHEMICAL APPROACH FOR SELECTIVE AND SENSITIVE DETECTION OF
OPIOID PEPTIDES
Sineadh, Conway, Anesthesiology, United States98.

IN SILICO¬BASED MOLECULAR CHARACTERIZATION OF SELECTED G PROTEINBIASED AGONISTS OF MU OPIOID RECEPTOR
Sabina, Podlewska, Maj Institute of Pharmacology, Polish Academy of Sciences (IF PAS), Poland

101. KAPPA RECEPTOR PARTIAL AGONISTS INACTIVATE KOR THROUGH A JNK/ROS
MECHANISM
Carlie, Neiswanger, University of Washington - Department of Pharmacology, United States
28.

MU OPIOID RECEPTORS IN VGLUT2-EXPRESSING GLUTAMATERGIC NEURONSMODULATE OPIOID AVERSION
Kaitlin, Reeves, Indiana University School of Medicine, United States

50.

DORSAL HIPPOCAMPUS ACTIVATION OF ACCUMBAL DYNORPHIN NEURONS DRIVE
REINFORCEMENT.
Khairunisa, Ibrahim, Washington University in St. Louis, United States

76.

KAPPA OPIOID RECEPTOR CURRENTS IN MOUSE PARAVENTRICULAR THALAMUS
Eloise, Kuijer, University of Bath, United Kingdom

79.

TEMPORAL DYNAMICS OF LOCUS COERULEUS MODULATION OF STRESS-INDUCEDANTINOCICEPTION
Makenzie, Norris, Center for Clinical Pharmacology, United States

89.

MU-OPIOID RECEPTOR ACTIVATION IN THE VENTRAL TEGMENTAL AREA AND ITSIMPACT ON MICROGLIAL PROLIFERATION: ROLE OF INFLAMMATORY PAINDavid, Meseguer, Faculty of Pharmacy - University of Valencia, España

106. ACUTE STRESS SHIFTS KAPPA-OPIOID RECEPTOR FUNCTION FROM INHIBITORY TO
EXCITATORY IN A SUBSET OF VTA DOPAMINE NEURONS
Elyssa, Margolis, UCSF, United States
26 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

Nazzareno, Cannella, School fo Pharmacy, University of Camerino, Italy
122. HETEROGENOUS TOLERANCE TO SNC-80 AT SOMATIC AND PRESYNAPTIC DELTAOPIOID RECEPTORS IN THE ANTERIOR CINGULATE CORTEXMarie, Walicki, University of Michigan, United States
124. ROLE OF RMTG (TAIL OF THE VTA) ON THE ETHANOL-DERIVED ACTIVATION OF VTADA NEURONS.
Claudia, Esposito, Universitat de Valencia, España
37.

INFLUENCE OF PSYCHEDELIC PSILOCYBIN ON OXYCODONE-INDUCED CONDITIONEDPLACE PREFERENCE IN C57BL/6 MALE AND FEMALE MICE
Alaina, Jaster, Virginia Commonwealth University, United States

74.

ADS012, A SINGLE STRAIN LIVE BIOTHERAPEUTIC PRODUCT, ATTENUATESTOLERANCE TO REPEATED MORPHINE DOSING IN MICE
Chesnel, Laurent, Adiso Therapeutics, United States

81.

IMPACT OF Δ9-TETRAHYDROCANNABINOL ADMINISTRATION ON MEASURES OFOXYCODONE-INDUCED ANTINOCICEPTION, DEPENDENCE AND REWARD
Richard, Slivicki, Washington University, United States

93.

AKAP150 PRIMES PACLITAXEL-INDUCED PERSISTENT PAIN BY SYNCHRONIZINGPKA AND PKCΔ ACTIVATION
Ying, He, University of Illinois at Chicago, United States

112. NIH HETEROGENEOUS STOCK RATS TRAINED TO HEROIN SELF-ADMINISTRATIONSHOW HETEROGENEOUS RESPONSE TO THE ANTI-ADDICTIVE EFFECTS OF THE
MOP/NOP AGONIST CEBRANOPADOL
Nazzareno, Cannella, School fo Pharmacy, University of Camerino, Italy
128. NEW NOSE-TO-BRAIN LIPOSOMAL PHARMACEUTICAL FORMULATION TARGETINGTHE KAPPA OPIOID RECEPTOR
Lucia, Hipolito, Universitat Valencia, España
38.

HELPING KIDS PROSPER IN UTAH: AN EVIDENCE-BASED, COMMUNITY APPROACH
TO PREVENTION
Claire, Warnick, Utah State University, United States

90.

ETHANOL-INDUCED DOPAMINE RELEASE IN THE NUCLEUS ACCUMBENS CORE IN
PRE-EXPOSED ANIMALS TO ALCOHOL: ROLE OF INFLAMMATORY PAIN
Ana, Riera, Faculty of Pharmacy, University of Valencia, España

100. OREXIN-RECEPTOR ANTAGONIST EFFECTS ON SLEEP AND STRESS DURING OPIOIDWITHDRAWAL: A RANDOMIZED-CONTROLLED TRIAL
Andrew, Huhn, Johns Hopkins University, United States
110. OPIOID USE DISORDER IS ASSOCIATED WITH ALTERATIONS IN CIRCADIANPATHWAYS: PROTEOMICS ANALYSIS OF HUMAN POSTMORTEM BRAINS.
Stephanie, Puig, Boston University Scool of Medicine, United States
111. LONG ACCESS HEROIN SELF-ADMINISTRATION INDUCES GREY MATTER VOLUME
REDUCTION IN NIH HETEROGENEOUS STOCK RATS.
Nazzareno, Cannella, School fo Pharmacy, University of Camerino, Italy
126. THE INFLUENCE OF THE GUT MICROBIOTA DURING OPIOID WITHDRAWAL
Julia, Nickols, University of Alberta, Canada
127. HIPPOCAMPAL MU OPIOID AND CANNABINOID 1 RECEPTORS ARE MODULATED| 27

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

FOLLOWING COCAINE SELF-ADMINISTRATION IN MALE RATS
Befort, Katia, Université de Strasbourg, CNRS, UMR7364, France
138. OXYTOCIN AND OREXIN SYSTEMS BIDIRECTIONALLY REGULATE THE ABILITY OFOPIOID CUES TO BIAS CHOICE DURING RELAPSE
Giuseppe, Giannotti
52.

SEX DIFFERENCES IN EPIGENETIC MECHANISMS OF OPIOIDS
Falconnier Camille, Falconnier, INCI CNRS UPR 3212, France

71.

PREDICTION OF MORPHINE AND PREGABALIN THERAPEUTIC CONCENTRATIONSAT THE BRAIN EXTRACELLULAR FLUID AND EVALUATION OF THEIR EFFECTS ON
NEURONAL GENE EXPRESSION OF TARGETS INVOLVED IN PAIN AND ANALGESIA
Andrea, Bedini, Dept. Pharmacy and Biotechnology - University of Bologna, Italy

70.

EXAMINING THE ASSOCIATION OF CHRONIC PAIN, GENDER, AND OPIOIDWITHDRAWAL SEVERITY DURING THE FIRST WEEK OF TREATMENT
Orrin, Ware, Johns Hopkins University School of Medicine, United States

95.

ALTERATIONS IN ASTROCYTES AND THE GLUTAMATE TRANSPORTER GLT-1 IN THE
PREFRONTAL CORTEX INDUCED BY INFLAMMATORY PAIN: SEX PERSPECTIVE
Paula, Andrés, Faculty of Pharmacy, University of Valencia, España

125. OPIOID ANALGESIA IN A MODEL OF PAIN-DEPRESSED BEHAVIOR IN MICE: ROLE OF
MU OPIOID RECEPTOR AGONIST EFFICACY
Steve, Negus, Virginia Commonwealth University, United States
133. HYDROGEN SULFIDE INCREASES THE ANTIALLODYNIC EFFECTS OF MORPHINE IN
ANIMALS WITH NEUROPATHIC PAIN
Olga, Olga, Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), España
53.

DOES MICROGLIA-ASTROCYTE CROSSTALK ORCHESTRATE SEX DIFFERENCES IN
MORPHINE CENTRAL METABOLISM AND ITS ANTINOCICEPTIVE EFFECTS?
Volodya ,HOVHANNISYAN. Institut des Neurosciences Cellulaires et Intégratives, France

61.

PAIN-DEPRESSED CLIMBING AND AGONIST/ANTAGONIST OPIOID MIXTURES IN
MALE AND FEMALE MICE AS TOOLS FOR ANALGESIC DRUG DEVELOPMENT
Edna, Santos, VCU. United States

137. AUTOPHAGY INDUCTION VIA Κ-OPIOID RECEPTOR IS IMPLICATED IN STRESSDRIVEN SYNAPTIC ALTERATIONS
Christos, Karoussiotis Greece
131. CHARACTERIZATION OF TWO SUBPOPULATIONS IN A COHORT OF FEMALE WISTAR
RATS: A GENDER STUDY UNDER THE ADE MODEL
Sandra, Fernández, University of Valencia, España
57.

NEGATIVE AFFECT IS ASSOCIATED TO OPIOID MEDICATION MISUSE: A TRANSVERSALSTUDY IN NON-CANCER CHRONIC PAIN PATIENTS
Lucia, Hipolito. Universitat Valencia

SESSION POSTER 2
68.

28 |

POSITIVE ALLOSTERIC MODULATION OF THE MU OPIOID RECEPTOR: STUDIES IN VIVO
Kelsey, Kochan, University of Michigan, United States

Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

80.

KINETICS OF FENTANYLS AND NITAZENES BINDING TO THE MU OPIOID RECEPTOR
Norah Alhosan, Norah, UoB, United Kingdom
87. STRUCTURE, FUNCTION, AND PHARMACOLOGY OF DELTA OPIOID RECEPTOR
BITOPIC LIGANDS
Sarah, Bernhard, Washington University in St. Louis, United States
96. OPIOID EFFECTS ON OXIDATIVE STRESS AND PROTEASOME ACTIVITY IN HUMAN
NEUROBLASTOMA SH-SY5Y CELLSPatrizia, Romualdi, Dept. Pharmacy & Biotechnology, Italy
99. ADDICTION-RELATED BEHAVIORAL EFFECTS OF G PROTEIN-BIASED AGONISTS OF
THE Μ-OPIOID RECEPTOR
Lucja, Kudla, Maj Intitute of Pharmacology, Polish Academy of Sciences, Poland
117. THE GI-PROTEIN COUPLED RECEPTORS MOR AND GPR151 CONTRIBUTE TO SOCIALREWARD IN THE HABENULA
Allain, Florence, INSERM, France
121. MOTOR CORTEX STIMULATION-INDUCED ANTINOCICEPTION REQUIRESENDOGENOUS OPIOID SIGNALING
Nicole, Mercer, Stanford University, United States
136. INFRARED AND NEAR-INFRARED FLUORESCENT OPIOID ANTAGONISTS:
ALTERNATIVE TO RADIOLIGAND BASED ASSAYS
Brian, Reed, Rockefeller University, United States
33. CONTRIBUTION OF THE CENTRAL AMYGDALA TO PAIN HYPERSENSITIVITY IN A
MOUSE MODEL OF MULTIPLE SCLEROSIS
Zoë, Dworsky-Fried, University of Alberta, Canada
59. MU OPIOID RECEPTOR-MEDIATED EFFECTS OF MOR AGONISTS ON WHOLE BRAINFUNCTIONAL CONNECTIVITY IDENTIFIED BY MOUSE FMRI.
Darcq, Emmanuel, INSERM, France
69. DISSECTING THE ACCUMBAL DYNORPHINERGIC OUTPUTS UNDERLYING AFFECTIVE PAIN
Nicolas, Massaly, Washington University in St Louis, United States
77. DISSECTING THE EFFECT OF STRESS ON ENDOGENOUS NOCICEPTIN CIRCUITRY IN
THE VENTRAL TEGMENTAL AREA
Carolyn, Stine, University of Washington, United States
86. CHRONIC MORPHINE DIFFERENTIALLY ALTERS OPIOID EFFICACY AT SOMATIC ANDPRESYNAPTIC MORS WITHIN A THALAMO-CORTICO-STRIATAL MICROCIRCUIT
Elizabeth, Jaeckel, University of Michigan, United States
97. MU-OPIOID RECEPTORS IN THE BNST MEDIATE MORPHINE ANTINOCICEPTION
Arbi, Nazarian, WesternU, College of Pharmacy, United States
104. UNCOVERING THE RELEASE DYNAMICS OF ENKEPHALINS FOLLOWING ACUTE STRESS
Marwa, Mikati, Washington University in St. Louis, United States
108. PAIN-ASSOCIATED FENTANYL INTAKE IN MALES IS DRIVEN BY DYAMIC ACTIVITY OF
VENTRAL TEGMENTAL AREA DOPAMINE NEURONS
Jessica, Higginbotham, Washington University, United States
119. UNCOVERING THE DYNORPHINERGIC PROJECTION OF CENTRAL AMYGDALA TO
NUCLEUS ACCUMBENS: ROLE ON PAIN-INDUCED NEGATIVE AFFECT.
Jesús David, Lorente, Department of Pharmacy and Pharmaceutical Technology. University of
Valencia, España| 29

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

120. INFLAMMATORY PAIN INDUCES ANXIETY- AND ANHEDONIA-LIKE BEHAVIOR IN
A SEX-DEPENDENT MANNER: ROLE OF DYNORPHINERGIC AND CORTICOTROPINRELEASING SYSTEMS IN THE MCLS.
Jesús David, Lorente, Department of Pharmacy and Pharmaceutical Technology. University of
Valencia, España
139. Ventral pallidal perineuronal nets regulate opioid relapse
Carley N., Miller
60.

STRUCTURE ACTIVITY RELATIONSHIPS OF FENTANYL ANALOGS
Jessica, Anand, University of Michigan, United States

66.

NEW SYNTHETIC OPIOIDS USE AMONG PATIENTS IN TREATMENT FOR AN OPIOIDUSE DISORDER IN BARCELONA
María, Alías, IMIM, España

78.

SEX DIFFERENCES IN THE ROLE OF CNIH3 IN OPIOID SEEKING
Tania, Lintz, Washington University in St. Louis, United States

85.

EXPLORING GPR171 AGONISTS AS NOVEL PAIN THERAPEUTICS
Max, McDermott, Utah State University, United States

107. PPL-138: A BIFUNCTIONAL NOP/MU PARTIAL AGONIST THAT REDUCES COCAINESELF-ADMINISTRATION IN RATS
Madeline, Martinez, Florida Atlantic University, United States
114. TARGETING PDGFR-BETA TO MAKE OPIOID PRESCRIPTIONS SAFER
Luca, Posa, Boston University, United States
129. PHOSPHOLIPASE CGAMMA1 IN THE NUCLEUS ACCUMBENS ALTERS HEROINSEEKING BEHAVIOR
Ethan, Anderson, Medical University of South Carolina, United States
45.

ADMINISTRATION OF HUMAN MESENCHYMAL STEM CELLS-DERIVED SECRETOME
MARKEDLY INHIBITS ORAL MORPHINE SELF-ADMINISTRATION AND BLOCKSRELAPSE IN TWO RAT MODELS OF MORPHINE DEPENDENCE
Fernando, Ezquer, Center for Regenerative Medicine, School of Medicine, Universidad delDesarrollo, Chile

92.

SYSTEMIC AND INTRANASAL ADMINISTRATION OF MESENCHYMAL STEM CELLDERIVED SECRETOME REDUCES THE WITHDRAWAL SYNDROME CAUSED BYOPIOID ADMINISTRATION IN RATS
Mauricio, Quezada, Universidad del Desarrollo, Chile

51.

POSITIVE AND NEGATIVE REINFORCEMENT AMONG LONG-TERM HEROIN USERS:ASSESSMENT OF SUBJECTIVE EXPERIENCE OF HEROIN EFFECTS AS A SURROGATEMEASURE
Suky, Martinez, Columbia University, United States

65.

EVIDENCE FOR HEROIN-INDUCED SOCIAL ISOLATION IN THE RAT
Ginevra, D’Ottavio, Sapienza University of Rome, Italy

102. INSOMNIA IS ASSOCIATED WITH PREMATURE TREATMENT DISCONTINUATION
AND DEPRESSIVE SYMPTOM SEVERITY IN PERSONS ENTERING TREATMENT FOROPIOID USE DISORDER
Jennifer D Ellis, Jennifer, Johns Hopkins School of Medicine, United States
30 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

109. HEROIN-NAÏVE NIH HETEROGENEOUS STOCK RATS VULNERABLE TO OPIOID USE
DISORDERS SHOW REDUCED RESPONSE TO THE ANALGESIC EFFECT OF HEROIN
Nazzareno, Cannella, School fo Pharmacy, University of Camerino, Italy
115. THE ENDOCANNABINOID ENZYME NAPE-PLD REGULATES ANXIETY-LIKE BEHAVIORSAND THE REINFORCING PROPERTIES OF ORAL OXYCODONE CONSUMPTION IN MICE
Taylor Woodward, Taylor, IU Bloomington, United States
116. HEALING PLACES, HEALING PEOPLE: INSIGHTS ON SPONTANEOUS CRITICAL PLACEMAKING FROM AN OPIATE SUBSTITUTE THERAPY PROGRAMME IN DURBAN,
SOUTH AFRICA
Michael, Wilson, Bellhaven Harm Reduction Centre, South Africa
132. WHAT IS THE THERAPEUTIC BLOOD LEVEL OF NALTREXONE FOR OUD TREATMENT?
Felipe, Castillo, NYSPI/Columbia University, United States
62.

NO EVIDENCE OF ACCELERATED EPIGENETIC AGING AMONG BLACK HEROIN
USERS: A CASE VS CONTROL ANALYSIS.
Jermaine, Jones, Columbia University College of Physicians and Surgeons, United States

88.

DEVELOPMENT OF NOVEL THERAPEUTIC TARGETS FOR THE TREATMENT OFOPIOID INDUCED HYPERALGESIA.
Elizaveta, Mangutov, UIC, United States

105. CYCLO-GLYCOPEPTIDE DRUGS FOR PAIN MANAGEMENT: OPIOID AND NONOPIOID EXAMPLES
Robin, Polt, Chemistry & Biochemistry, BIO5, United States
130. HYDROGEN SULFIDE ENHANCES THE ANALGESIC PROPERTIES OF DELTA OPIOID
RECEPTORS DURING INFLAMMATORY PAIN
Olga, Olga, Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), España
82.

CHARACTERISATION OF CARFENTANIL DEPRESSION OF RESPIRATION IN MICE
Damiana Cavallo, Damiana, University of Bristol, United Kingdom

75.

DISRUPTION OF VAGAL-BRAINSTEM CONNECTIONS DOES NOT ALTER FENTANYLINDUCED RESPIRATORY DEPRESSION
Brian Ruyle, Brian, Washington University in St Louis, United States

84.

EFFECTS OF COCAINE ON OXYCODONE- AND FENTANYL-INDUCED VENTILATORY
DEPRESSION IN MICE
Harrison Elder, Harrison, Virginia Commonwealth University, United States

118. CHRONIC NALTREXONE THERAPY IMPROVED CARDIAC FUNCTION IN VOLUMEOVERLOAD-INDUCED HEART FAILURE
Schaefer, Michael, Anaesthesiology, Charité University Berlin, Germany
113. MARCHIGIAN SARDINIAN ALCOHOL PREFERRING RATS SHOW INCREASED HEROIN
SELF-ADMINISTRATION AND MOTIVATION COMPARED TO NON-PREFERRINGWISTAR RATS: INVESTIGATING THE ROLE OF THE NOP/MOP SYSTEM.
63.

OPIOID WITHDRAWAL POTENTIATES SYNAPTIC OUTPUT FROM THE VENTRALPALLIDUM TO THE LATERAL HABENULA
Jessica, Tooley, Washington University in St. Louis, United States

67.

INVESTIGATING SPATIO-TEMPORAL BIAS AT THE MU-OPIOID RECEPTOR
Rebecca, Annells, University of Bath, United Kingdom| 31

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

RELEVANT INFORMATION• VENUE:
Hotel Melia Valencia 4*
Avda. Cortes Valencianas, 52. 46015 Valencia• PLENARY SESSIONS: Valentia B + C (Main room)• POSTER SESSION: Valentia A room
• MENTORING ACTIVITIES: Terra room
• COFFE BREAK: Hall of Hotel• CONFERENCE PROGRAM LUNCHES: Terra room
• SOCIAL EVENTS:
WELCOME
Monday, 4th July. 07:00-08:00 pm
Melia Valencia 4* (at the Hall)
INRC BAR
Wednesday, 6th July 08:30-09:30 pm
Àtic-Palau Alameda
Calle de Muñoz Seca, 1. 46010 Valencia
No ticket need
GET TOGHETER
Thrusday, 7th July 08:00-09:30 pm
Restaurante Contrapunto Les Arts
Av. del Profesor López Piñero, 1. 46013 Valencia
GALA DINNER
Friday, 8th july, 08:30 pm
Hotel Balneario Las Arenas 5*
Calle Eugenia Viñes, 22, 24. 46011 Valencia– Bring the gala dinner with you.
– Ask to Technical Secretariat (registration point) for the bus departure.

32 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

EXHIBITOR AREAUE
VEN CEAN
R
ENT

VALENTIAA
AL
NIC RIATCHTE RETACSE

HIBITION AREA

- EX
FOYER VALENTIA

VALENTIA
B+C

STAND

| 33

“NEW ADVANCES IN OPIOID RESEARCH: FROM BENCH TO THE BEDSIDE”
2022

INRC

PARTNERS

34 |Valencia (Spain)
4th-8th July 2022 | Hotel Meliá Valencia

NOTES

| 35

“

NEW ADVANCES IN OPIOIDRESEARCH: FROM BENCH
TO THE BEDSIDE

”

INRC
2022

VALENCIA (SPAIN)
4th-8th July 2022 | Hotel Meliá Valencia

Technical Secretary:
MICE VALENCIA
C.C. Ademuz • Av. Pío XII, 51 - 4ª Floor
46015 VALENCIA (Spain)
Tel. (+34) 96 310 71 89
inrc2022@viajeseci.es